AMD3100 efficacy in hematopoietic stem cell mobilization was tested in two successful randomized phase III clinical trials on HIV-1 patients (DiPersio et al., 2009) and it was approved by FDA and EMA, in association with G-CSF, for autologous bone marrow transplantation in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL)(De Clercq, 2010). This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.